JP2021519302A - 微小残存がんを治療する方法 - Google Patents

微小残存がんを治療する方法 Download PDF

Info

Publication number
JP2021519302A
JP2021519302A JP2020551836A JP2020551836A JP2021519302A JP 2021519302 A JP2021519302 A JP 2021519302A JP 2020551836 A JP2020551836 A JP 2020551836A JP 2020551836 A JP2020551836 A JP 2020551836A JP 2021519302 A JP2021519302 A JP 2021519302A
Authority
JP
Japan
Prior art keywords
cancer
subject
cells
her2
perk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020551836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519302A5 (https=
JPWO2019191115A5 (https=
Inventor
ジュリオ エー． アギーレ−ギゾー
ジュリオ エー． アギーレ−ギゾー
Original Assignee
アイカーン スクール オブ メディシン アット マウント サイナイ
アイカーン スクール オブ メディシン アット マウント サイナイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイカーン スクール オブ メディシン アット マウント サイナイ, アイカーン スクール オブ メディシン アット マウント サイナイ filed Critical アイカーン スクール オブ メディシン アット マウント サイナイ
Publication of JP2021519302A publication Critical patent/JP2021519302A/ja
Publication of JP2021519302A5 publication Critical patent/JP2021519302A5/ja
Publication of JPWO2019191115A5 publication Critical patent/JPWO2019191115A5/ja
Priority to JP2023147297A priority Critical patent/JP7719135B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020551836A 2018-03-26 2019-03-26 微小残存がんを治療する方法 Pending JP2021519302A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023147297A JP7719135B2 (ja) 2018-03-26 2023-09-12 微小残存がんを治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648166P 2018-03-26 2018-03-26
US62/648,166 2018-03-26
PCT/US2019/024097 WO2019191115A1 (en) 2018-03-26 2019-03-26 Methods of treating minimal residual cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023147297A Division JP7719135B2 (ja) 2018-03-26 2023-09-12 微小残存がんを治療する方法

Publications (3)

Publication Number Publication Date
JP2021519302A true JP2021519302A (ja) 2021-08-10
JP2021519302A5 JP2021519302A5 (https=) 2022-04-04
JPWO2019191115A5 JPWO2019191115A5 (https=) 2022-04-04

Family

ID=68060400

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020551836A Pending JP2021519302A (ja) 2018-03-26 2019-03-26 微小残存がんを治療する方法
JP2023147297A Active JP7719135B2 (ja) 2018-03-26 2023-09-12 微小残存がんを治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023147297A Active JP7719135B2 (ja) 2018-03-26 2023-09-12 微小残存がんを治療する方法

Country Status (14)

Country Link
US (1) US20210121527A1 (https=)
EP (1) EP3775171B1 (https=)
JP (2) JP2021519302A (https=)
KR (1) KR102897382B1 (https=)
CN (1) CN112166187B (https=)
AU (1) AU2019243443B2 (https=)
BR (1) BR112020019023A2 (https=)
CA (1) CA3095156A1 (https=)
EA (1) EA202092282A1 (https=)
ES (1) ES2975770T3 (https=)
IL (2) IL277568A (https=)
MX (1) MX2020009922A (https=)
WO (1) WO2019191115A1 (https=)
ZA (1) ZA202005723B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022546410A (ja) * 2019-08-29 2022-11-04 ヒベルセル， インコーポレイテッド Ｐｅｒｋ阻害化合物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11815435B2 (en) 2017-02-24 2023-11-14 Hibercell, Inc. Beta glucan immunopharmacodynamics
PL4039675T3 (pl) 2017-04-18 2025-01-07 Eli Lilly And Company Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe
WO2021231782A1 (en) * 2020-05-13 2021-11-18 Hibercell, Inc. Perk inhibitors for treating viral infections
CN113604436A (zh) * 2021-08-11 2021-11-05 清华大学深圳国际研究生院 一种肿瘤内分泌药物诱导的休眠或复发细胞株的构建方法
CA3269342A1 (en) * 2022-10-04 2024-04-11 Hibercell, Inc. Perk inhibitor hc-5404 in combination with anti-pd-1 antibody and/or an antiangiogenetic agent for use in the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030933A2 (en) * 2003-09-24 2005-04-07 Genera Doo Bone morphogenetic protein (bmp)-7 based diagnosis and treatment of cancer
NZ617520A (en) * 2008-02-25 2015-05-29 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
PL4039675T3 (pl) 2017-04-18 2025-01-07 Eli Lilly And Company Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C M TATE; ET AL: "A BMP7 VARIANT INHIBITS THE TUMORIGENIC POTENTIAL OF GLIOBLASTOMA STEM-LIKE CELLS", CELL DEATH DIFFERENTIATION, vol. VOL:19,NR:10, JPN5021008457, 27 April 2012 (2012-04-27), pages 1 - 11, ISSN: 0005195708 *
J. EXP. MED., 2011, VOL.208, NO.13, PP.2641-2655, JPN6023011110, ISSN: 0005195709 *
JULIO A AGUIRRE-GHISO; ET AL: "TARGETING DORMANT CANCER", NATURE MEDICINE, vol. VOL:19,NR:3, JPN5021008455, 6 March 2013 (2013-03-06), pages 1 - 4, ISSN: 0005195707 *
MARIA SOLEDAD SOSA; ET AL: "MECHANISMS OF DISSEMINATED CANCER CELL DORMANCY: AN AWAKENING FIELD", NATURE REVIEWS CANCER, vol. VOL:14,NR:9, JPN5021008461, 14 August 2014 (2014-08-14), pages 1 - 27, ISSN: 0005195711 *
MIGUEL VIZARRETA SANDOVAL; ET AL: "ABSTRACT A45: PERK-INHIBITION AS A POSSIBLE THERAPY FOR HYPOXIA-INDUCED SOLITARY DORMANT TUMOR CELLS", CANCER RESEACH, vol. VOL:76,NR:7S, JPN5021008459, April 2016 (2016-04-01), pages 1 - 4, ISSN: 0005195710 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022546410A (ja) * 2019-08-29 2022-11-04 ヒベルセル， インコーポレイテッド Ｐｅｒｋ阻害化合物

Also Published As

Publication number Publication date
AU2019243443A1 (en) 2020-10-15
EA202092282A1 (ru) 2021-01-14
EP3775171A1 (en) 2021-02-17
CN112166187B (zh) 2025-06-20
EP3775171A4 (en) 2022-06-15
ZA202005723B (en) 2025-11-26
IL277568A (en) 2020-11-30
JP7719135B2 (ja) 2025-08-05
CN112166187A (zh) 2021-01-01
AU2019243443B2 (en) 2025-05-22
BR112020019023A2 (pt) 2020-12-29
US20210121527A1 (en) 2021-04-29
KR102897382B1 (ko) 2025-12-08
EP3775171B1 (en) 2024-01-03
KR20200139188A (ko) 2020-12-11
WO2019191115A4 (en) 2019-12-05
ES2975770T3 (es) 2024-07-15
IL286297A (en) 2021-10-31
JP2023175773A (ja) 2023-12-12
CA3095156A1 (en) 2019-10-03
WO2019191115A1 (en) 2019-10-03
MX2020009922A (es) 2020-10-14

Similar Documents

Publication Publication Date Title
JP7719135B2 (ja) 微小残存がんを治療する方法
Mourskaia et al. ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone
Trimmer et al. CAV1 inhibits metastatic potential in melanomas through suppression of the integrin/Src/FAK signaling pathway
S Steelman et al. Critical roles of EGFR family members in breast cancer and breast cancer stem cells: targets for therapy
Chang et al. Regulation of metastatic ability and drug resistance in pulmonary adenocarcinoma by matrix rigidity via activating c-Met and EGFR
WO2019237688A1 (zh) C型1类尼曼-匹克蛋白在癌症诊疗中的应用
Kietzman et al. Short-and long-term effects of CDK4/6 inhibition on early-stage breast cancer
JP2023156343A (ja) がん幹細胞の低減におけるｗｎｔ５ａペプチド
US20250339549A1 (en) Methods for the detection and treatment of non-small-cell lung cancer
CN116783311A (zh) Hormad1疗法
CN115006538A (zh) Sdcbp抑制剂在制备抗食管癌药物中的应用
HK40046184A (en) Methods of treating minimal residual cancer
HK40046184B (en) Methods of treating minimal residual cancer
Jindal et al. Milciclib and sorafenib synergistically downregulate c-Myc to suppress tumor growth in an orthotopic murine model of human hepatocellular carcinoma
Sun et al. DB75 targets PRMT1 to suppress liver metastasis and synergizes with PD-L1 blockade for enhanced therapeutic efficacy
Xiang et al. EID3 promotes glioma cell proliferation and survival by inactivating AMPKα1
Li Notch1 signaling plays an essential role in metabolic rewiring in chemoresistance prostate cancer
JP2020061973A (ja) 大腸癌患者の選択方法
Adebayo Role of Tumor Oxygen Tension in Signaling and Response to Targeted Therapies
Zhang et al. Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits TGFβ1 Induced Lung and Tumor Fibrosis
McClellan et al. Reprogramming the Immune Suppressive Tumor Microenvironment in Glioma Enhances the Efficacy of Immune-Mediated Gene Therapy
Liu et al. I engar, PV,… Di ke, P. ten.(2020). Deubiquitinase acti it profiling identifies UCHL1 as a candidate oncoprotein that promotes TGF beta-induced breast cancer metastasis.,(6), 1460-1473. doi: 10.1158/1078-0432
Flynn 6 Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (pfkfb3): A Critical Mediator of Breast Cancer Metastasis and Escape from Dormancy
CN112168828A (zh) 一种egfr与cdk4/6小分子靶向药组合物及其应用
CN118252922A (zh) Sirt6激活剂mdl-800在乳腺癌逆转治疗抵抗与化疗耐药中的应用

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230320

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230619

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231114